Figure 1.
Study design and patient disposition in this phase II study evaluating efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.